Neurotoxicity of BFM-95 on the medial olivocochlear bundle assessed by means of contralateral suppression of 2f1-f2 distortion product otoacoustic emissions

Otology and Neurotology

Volumn 28, Issue 2, 2007, Pages 208-212

  Riga, Maria ^a,d   Korres, Stavros ^b   Psarommatis, Ioannis ^c   Varvutsi, Maria ^b   Giotakis, Ioannis ^c   Papadas, Theodoros ^a   Ferekidis, Eleftherios ^b   Apostolopoulos, Nikolaos ^c  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c P AND A KYRIAKOU CHILDREN S HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

Distortion product otoacoustic emissions; Neurotoxicity; Suppression; Vincristine

Indexed keywords

CYTARABINE; GENTAMICIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BERLIN FRANKFURT MUNSTER 95; CANCER CHEMOTHERAPY; CELL FUNCTION; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; HAIR CELL; HUMAN; NEUROTOXICITY; OTOACOUSTIC EMISSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURE TONE AUDIOMETRY; TINNITUS; VERTIGO; WHITE NOISE;

ACOUSTIC STIMULATION; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUDIOMETRY, PURE-TONE; AUDITORY PATHWAYS; CHILD; COHORT STUDIES; GENTAMICINS; HEARING LOSS, SENSORINEURAL; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, ACUTE; OLIVARY NUCLEUS; OTOACOUSTIC EMISSIONS, SPONTANEOUS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VINCRISTINE;

EID: 33846645439     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e31802ce486     Document Type: Article

References (35)

1. Reinders-Messelink H, Van Weerden T, Fock J, et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur J Paediatr Neurol 2000;4:225-33.
2. Halsey K, Skjonsberg A, Ulfendahl M. Efferent-mediated adaptation of the DPOAE as a predictor of aminoglycoside toxicity. Hear Res 2005;201:99-108.
3. Stavroulaki P, Apostolopoulos N, Dinopoulou D, Vossinakis I, Tsakanikos M, Douniadakis D. Otoacoustic emissions-an approach for monitoring aminoglycoside induced ototoxicity in children. Int J Pediatr Otorhinolaryngol 1999;50:177-84.
4. Lugassy G, Shapira A. A prospective cohort study of the effect of vincristine on audition. Anticancer Drugs 1996;7:525-6.
5. Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut 1990;61:320-1.
6. Aydogdu I, Ozturan O, Kuku I, et al. Bilateral transient hearing loss associated with vincristine therapy: case report. J Chemother 2000;12:530-2.
7. Serafy A. The effect of vincristine on the neurological elements of the rabbit cochlea. J Laryngol Otol 1981;95:49-54.
8. Hotz MA, Harris FP, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope 1994;104:1130-4.
9. Subramaniam M, Salvi RJ, Spongr VP, et al. Changes in distortion product otoacoustic emissions and outer hair cells following interrupted noise exposures. Hear Res 1994;74:204Y16.
10. Moffat DA, Ramsden RT. Profound bilateral sensorineural hearing loss during gentamicin therapy. J Laryngol Otol 1977;91:511-6.
11. Esterhai JL Jr, Bednar J, Kimmelman CP. Gentamicin-induced ototoxicity complicating treatment of chronic osteomyelitis. Clin Orthop Relat Res 1986;209:185-8.
12. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia 1993;7:378-83.
13. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000;284:3043-5.
14. Goubin A, Auclerc MF, Auvrignon A, et al. Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000). Eur J Cancer 2006;42:534-41.
15. Kong W, Yang Y, Zhang W. Contralateral suppression of latency during distortion product otoacoustic emissions detection in guinea pigs. Zhonghua Er Bi Yan Hou Ke Za Zhi 2001;36:271-4.
16. Hall JW. DPOAE measurement and analysis. In: Hall JW. Handbook of Otoacoustic Emissions. San Diego, CA: Singular Publishing Group, 2000:108-11.
17. Di Girolamo S, d' Ecclesia A, Quaranta N, Garozzzo A, Evoli A, Paludetti G. Effects of contralateral white noise stimulation on distortion product otoacoustic emissions in myasthenic patients. Hear Res 2001;162:80-4.
18. Kujawa S, Liberman C. Effects of olivocochlear feedback on distortion product otoacoustic emissions in guinea pig. J Assoc Res Otolaryngol 2001;2:268-78.
19. Zorowka P, Schmitt HJ, Eckel HE, Lippert KL, Schonberger W, Merz E. Serial measurements of transient evoked otoacoustic emissions (TEOAEs) in healthy newborns and in newborns with perinatal infection. Int J Pediatr Otorhinolaryngol 1993;27:245-54.
20. Lima da Costa D, Erre JP, Aran JM. Aminoglycoside ototoxicity and the medial efferent system: I. Comparison of acute and chronic gentamicin treatments. Audiology 1998;37:151-61.
21. Lima da Costa D, Erre JP, Pehourq F, Aran JM. Aminoglycoside ototoxicity and the medial efferent system: II. Comparison of acute effects of different antibiotics. Audiology 1998;37:162-73.
22. Kaplan RS, Wiernik PH. Neurotoxicity of antineoplastic drugs. Semin Oncol 1982;9:103-30.
23. McCarthy GM, Skillings JR. Jaw and other orofacial pain in patients receiving vincristine for the treatment of cancer. Oral Surg Oral Med Oral Pathol 1992;74:299-304.
24. Shelanski ML, Wisniewski H. Neurofibrillary degeneration induced by vincristine therapy. Arch Neurol 1969;20:199-206.
25. Lopez I, McKay DB. Effects of antimitotic agents on secretion and detergent extractability of adrenal nicotinic acetylcholine receptors. Cell Mol Neurobiol 1997;17:447-54.
26. Oakes SG, Santone KS, Powis G. Effect of some anticancer drugs on the surface membrane electrical properties of differentiated murine neuroblastoma cells. J Natl Cancer Inst 1987;79:155-61.
27. Fiekers JF. Effects of the aminoglycoside antibiotics, streptomycin and neomycin, on neuromuscular transmission: I. Presynaptic considerations. J Pharmacol Exp Ther 1983;225:487-95.
28. Fiekers JF. Effects of the aminoglycoside antibiotics, streptomycin and neomycin, on neuromuscular transmission: II. Postsynaptic considerations. J Pharmacol Exp Ther 1983;225:496-502.
29. Blanchet C, Erostegui C, Sugasawa M, Dulon D. Acetylcholine-induced potassium current of guinea pig outer hair cells: its dependence on a calcium influx through nicotinic-like receptors. J Neurosci 1996;16:2574-84.
30. + channels in single isolated cochlear efferent nerve terminals. Hear Res 1993;67:13-9.
31. Avan P, Erre JP, Lima da Costa D, et al. The efferent-mediated suppression of otoacoustic emissions in awake guinea pigs and its reversible blockade by gentamicin. Exp Brain Res 1996;109:9-16.
32. Aran JM, Erre JP, Avan P. Contralateral suppression of transient evoked otoacoustic emissions in guinea pigs: effects of gentamicin. Br J Audiol 1994;28:267-71.
33. Smith DW, Erre JP, Aran JM. Rapid, reversible elimination of medial olivocochlear efferent function following single injections of gentamicin in the guinea pig. Brain Res 1994;652:243-8.
34. Legha SS. Vincristine neurotoxicity, pathophysiology and management. Med Toxicol 1986;1:421-7.
35. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.